Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 22;12:6774. doi: 10.1038/s41467-021-27029-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — The TBCOX2 study was designed as a randomized, open label, controlled, four group multi-center phase I/II clinical trial with a final allocation ratio 1:1:1:1 to adjunctive interventions. Target number of participants was 10 per arm for the full analysis set (FAS). The first allocation ratio was 2:2:1:0 to (i) etoricoxib, (ii) H56:IC31 and (iii) controls. The second allocation, initiated following a passed interim analysis of safety (when the last participant in the first allocation had reached study day 98), had a ratio of 0:0:1:2 to (iii) controls and (iv) etoricoxib+H56:IC31. Oral administration (p.o.) of etoricoxib 120 mg was initiated within five days of initiation of standard tuberculosis (TB) treatment (182 days), and continued for 140 days. H56:IC31 5 μg intramuscular (i.m) was administered at day 84 and 140. Samples for immunogenicity analyses were harvested at denoted study days.